Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor ...

We are excited to announce clinical updates from our novel NLRP3 inhibitor portfolio, including topline results from the Phase 1 trial of VTX3232 in healthy ...

Ventyx Biosciences Announces Positive Preclinical Data for CNS ...

... medical need, today announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.

Ventyx Biosciences Reports Clinical Data for its NLRP3

We are excited to announce clinical updates from our novel NLRP3 inhibitor portfolio, including topline results from the Phase 1 trial of VTX3232 in healthy ...

Ventyx Biosciences Reports First Quarter 2024 Financial Results ...

Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 ... Our current pipeline includes internally discovered clinical programs targeting ...

Ventyx Biosciences Reports Third Quarter 2024 Financial Results ...

... NLRP3 Inhibitor): We initiated a Phase 2a trial ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Reports Positive Preclinical Results for NLRP3 ...

... its NLRP3 inhibitor VTX3232 in mice with diet-induced obesity (DIO). ... Start your data trial now! Synapse data is also accessible to ...

Ventyx Biosciences Reports Second Quarter 2024 Financial Results ...

“We are looking forward to advancing our portfolio of NLRP3 inhibitors into three Phase 2 clinical trials in the coming months with clinical ...

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its ...

“Inhibition of the NLRP3 inflammasome is emerging as a potent anti-inflammatory mechanism with therapeutic potential in a broad range of ...

Ventyx Biosciences Reports Fourth Quarter and Full Year

“This includes topline results from the Phase 2 trial of our peripheral NLRP3 inhibitor ... clinical programs targeting TYK2, S1P1R and NLRP3 ...

Ventyx Biosciences Announces $27 Million Strategic Investment ...

... NLRP3 inhibitor VTX3232. SAN DIEGO, Sept. 23, 2024 ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a ...

... NLRP3 inhibitor for the treatment of ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

News Releases – Ventyx Biosciences, Inc.

March 11, 2024. Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event · Read more.

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 ...

Pipeline Updates: VTX3232 (CNS-penetrant NLRP3 Inhibitor): The company completed a Phase 1 single- and multiple-ascending dose trial of VTX3232 ...

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 ...

... Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor. June 14 ... Our current pipeline includes internally discovered clinical ...

Ventyx-Biosciences-Reports-Clinical-Data-for-its ... - Larvol Delta

VTX002 - Ventyx Biosci. Zeposia (ozanimod) - BMS. Velsipity (etrasimod) - Pfizer. http://www.ncbi.nlm.nih.gov/pubmed/39252206. Laurent Peyrin-Biroulet; Sophie ...

Ventyx Biosciences Reports Second Quarter 2023 Financial Results ...

... trial of our CNS-penetrant NLRP3 inhibitor VTX3232 in healthy volunteers. ... Our current pipeline includes internally discovered clinical programs targeting TYK2 ...

EX-99.1 - SEC.gov

Exhibit 99.1. Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress. Topline Phase 1 data for our ...

Ventyx Biosciences Announces Positive Preclinical Data for CNS ...

... medical need, today announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models ...

Ventyx Biosciences Reports Third Quarter 2023 Financial Results ...

... data for our novel CNS penetrant NLRP3 inhibitor, VTX3232, in healthy volunteers. ... Our current pipeline includes internally discovered clinical programs ...

Ventyx Biosciences Reports Third Quarter 2024 Financial Results ...

We believe these data support the potential for VTX3232 as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory ...